---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product comparison"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product comparison. Topics: Competing products and development programs in uveal melanoma named by the sponsor, Treatments used in practice for advanced uveal melanoma: NICE committee description, Treatments used in practice for metastatic uveal melanoma: CADTH description of off-label immunotherapy, Tebentafusp label: HLA-A∗02:01-positive indication and genotyping requirement, and 22 further topics. 26 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/product-comparison"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Competing products and development programs in uveal melanoma named by the sponsor

> “For darovasertib, we are not aware of other companies actively developing clinical-stage therapeutics directed to PKC as a target for solid tumors.”
> “Replimune has initiated a potentially registration-enabling trial for RP-2, an oncolytic immunotherapy. iOnctura has initiated a Phase 2 trial for Roginolisib, an allosteric PI3K delta inhibitor, in 2L+ mUM.”
> “Other programs in development for mUM include Novartis’ DYP688, an ADC, with a GNAQ-11 inhibitor payload in a Phase 1/2 clinical trial, and Immatics’ anzu-cel/IMA203, a PRAME-targeting TCR-based, T cell therapy.”
> “Additionally, Immunocore has commercialized Tebentafusp, also known under its branded name as Kimmtrak, for the treatment of adult patients with HLA*A2(+), unresectable or metastatic UM.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

### Treatments used in practice for advanced uveal melanoma: NICE committee description

> “The clinical experts explained that the treatments used are those licensed for melanoma. These include pembrolizumab, nivolumab and ipilimumab immunotherapies, and dacarbazine chemotherapy. Most people with advanced uveal melanoma are offered pembrolizumab, and some people are offered ipilimumab with or without nivolumab. A small minority of people who cannot have immunotherapies are offered dacarbazine.”
> “A clinical expert noted that the nivolumab and ipilimumab combination has a higher toxicity profile than pembrolizumab or ipilimumab, so it is not used as often as other immunotherapies.”
> “The committee concluded that although pembrolizumab is the most common treatment option, there is no standard care for advanced uveal melanoma.”

Source: [NICE technology appraisal guidance TA1027, committee discussion (2025)](https://www.nice.org.uk/guidance/TA1027/chapter/committee-discussion)

<a id="topic-2.1.2.14-3"></a>

### Treatments used in practice for metastatic uveal melanoma: CADTH description of off-label immunotherapy

> “The most prescribed systemic therapies in a first-line setting are immunotherapies (off-label), given as monotherapies (i.e., nivolumab, or pembrolizumab alone), or in combination (i.e., ipilimumab plus nivolumab).”
> “Systemic chemotherapies have a limited role in the treatment of mUM in Canada, due to toxicity and a low response rate.”
> “According to the clinical expert, while immunotherapy is a reasonable first-line option, the response to immunotherapy is considered poor, and therefore clinical trials are preferred for patients in first line and beyond.”

Source: [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1)

<a id="topic-2.1.2.14-4"></a>

### Tebentafusp label: HLA-A∗02:01-positive indication and genotyping requirement

> “KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.”
> “Select patients for treatment of unresectable or metastatic uveal melanoma with KIMMTRAK based on a positive HLA-A*02:01 genotyping test of a whole blood sample [see Clinical Studies (14)].”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

### Tebentafusp label: weekly intravenous step-up dosing until progression

> “Recommended dosage: 20 mcg intravenously on Day 1, 30 mcg intravenously on Day 8, 68 mcg intravenously on Day 15, and 68 mcg intravenously once every week thereafter (2.2).”
> “Treat patients until unacceptable toxicity or disease progression occur.”
> “No dosage reduction for KIMMTRAK is recommended.”
> “Injection: 100 mcg/0.5 mL clear, colorless to slightly yellowish solution in a single-dose vial”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

### Tebentafusp label: administration setting, post-infusion monitoring, and two-step dilution

> “Administer the first three infusions of KIMMTRAK in an appropriate healthcare setting by intravenous infusion over 15-20 minutes. Monitor patients during the infusion and for at least 16 hours after the infusion is complete.”
> “If the patient does not experience Grade 2 or worse hypotension (requiring medical intervention) during or after the third infusion, administer subsequent doses in an appropriate ambulatory care setting, and monitor patients for a minimum of 30 minutes following each of these infusions [see Warnings and Precautions (5.1)].”
> “A 2-step dilution process is required for preparation of the final KIMMTRAK dose for infusion.”
> “Do not prepare more than one dose from the vial.”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

### Tebentafusp label: boxed warning for cytokine release syndrome and its incidence in IMCgp100-202

> “Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated”
> “CRS (≥ Grade 2) occurred in 77% of patients in Study IMCgp100-202 who received KIMMTRAK [see Adverse Reactions (6.1)].”
> “Among patients who received KIMMTRAK, 23% received systemic corticosteroids for at least 1 infusion, 8% received supplemental oxygen during at least 1 infusion, and 0.8% received a vasopressor for at least 1 infusion.”
> “CRS led to permanent discontinuation in 1.2% of patients.”
> “The majority (84%) of episodes of CRS started the day of infusion. Among cases that resolved, the median time to resolution of CRS was 2 days.”
> “Ensure that healthcare providers administering KIMMTRAK have immediate access to medications and resuscitative equipment to manage CRS.”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

### Tebentafusp label: skin reaction and liver enzyme warnings in IMCgp100-202

> “In study IMCgp100-202, skin reactions occurred in 91% of patients treated with KIMMTRAK, including Grade 2 (44%) and Grade 3 (21%) events.”
> “In Study IMC100-gp100-202, increases in alanine aminotransferase or aspartate aminotransferase were observed in 65% of patients treated with KIMMTRAK.”
> “Grade 3 or greater elevations in liver enzymes outside the setting of CRS occurred in approximately 8% of patients.”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

### Tebentafusp label: IMCgp100-202 design and population of 378 participants

> “KIMMTRAK was evaluated in IMCgp100-202, a randomized, open-label, multicenter trial (NCT03070392) that enrolled patients with metastatic uveal melanoma (N=378).”
> “Patients were excluded if they received prior systemic therapy for metastatic or advanced uveal melanoma or localized liver-directed therapy.”
> “The major efficacy outcome was overall survival (OS). Additional efficacy outcomes were investigator-assessed progression free survival (PFS) and objective response rate (ORR) per RECIST 1.1.”
> “The median age was 64 years (range 23 to 92 years); 50% were female; 87% were White, and 12% were unreported or unknown race.”
> “Baseline ECOG performance status was 0 (73%), 1 (21%), or 2 (0.3%); 36% had elevated LDH level; and 94% had liver metastasis.”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

### Tebentafusp label: IMCgp100-202 efficacy results versus investigator’s choice

| Outcome | KIMMTRAK (N=252) | Investigator’s choice of pembrolizumab, ipilimumab, or dacarbazine (N=126) |
| --- | --- | --- |
| Overall survival, number of deaths (%) | “87 (34.5%)” | “63 (50%)” |
| Overall survival, median in months (95% CI) | “21.7 (18.6, 28.6)” | “16 (9.7, 18.4)” |
| Progression-free survival, median in months (95% CI), final analysis | “3.3 (3, 5)” | “2.9 (2.8, 3)” |
| Objective response rate (95% CI), not formally tested | “9.1% (5.9, 13.4)” | “4.8% (1.8, 10.1)” |
| Complete response | “1 (0.4%)” | “0” |
| Partial response | “22 (8.7%)” | “6 (4.8%)” |

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

| Comparison, KIMMTRAK versus investigator’s choice | Hazard ratio (95% CI) |
| --- | --- |
| Overall survival, prespecified interim analysis, stratified by LDH status | “0.51 (0.37, 0.71)” |
| Progression-free survival, final analysis, stratified by LDH status | “0.73 (0.58, 0.94)” |

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

### Tebentafusp label: serious adverse reactions and discontinuation among patients who received KIMMTRAK in IMCgp100-202

> “Serious adverse reactions occurred in 28% of patients who received KIMMTRAK. Serious adverse reactions occurring in > 2% of patients were cytokine release syndrome (10%), rashes (4.5%), pyrexia (2.4%), and hypotension (2%). One patient (0.4%) experienced a fatal adverse reaction (pulmonary embolism).”
> “Adverse reactions led to permanent discontinuation in 3.3% of patients who received KIMMTRAK.”
> “The median duration of exposure was 5.3 months (range: 0.3 to 33 months) in patients treated with KIMMTRAK.”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

### Melphalan hepatic delivery system label: liver-directed indication restricted by hepatic tumor burden

> “HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.”

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

<a id="topic-2.1.2.14-13"></a>

### Melphalan hepatic delivery system label: intra-arterial dosing every 6 to 8 weeks for up to 6 infusions

> “HEPZATO, a component of the HEPZATO KIT, is administered by infusion into the hepatic artery (see IFU) every 6 to 8 weeks for up to 6 total infusions.”
> “The recommended HEPZATO dose is 3 mg/kg based on ideal body weight (IBW), as calculated per Table 1 below, with a maximum of 220 mg during a single treatment.”
> “Administer HEPZATO via the HEPZATO KIT Hepatic Delivery System only to patients weighing 35 kg or greater due to potential size limitations with respect to percutaneous catheterization.”
> “For injection: HEPZATO includes 50 mg freeze-dried (lyophilized) melphalan powder per vial in five (5) single dose vials, intended for reconstitution with the supplied diluents.”

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

<a id="topic-2.1.2.14-14"></a>

### Melphalan hepatic delivery system label: boxed warning, general anesthesia, and REMS-certified settings

> “Severe peri-procedural complications including hemorrhage, hepatocellular injury, and thromboembolic events may occur via hepatic intra-arterial administration of HEPZATO.”
> “Myelosuppression with resulting severe infection, bleeding, or symptomatic anemia may occur with HEPZATO.”
> “Administration of HEPZATO requires general anesthesia and extracorporeal bypass of circulation which may cause life threatening or fatal adverse effects.”
> “The HEPZATO KIT is only available through a restricted program under a REMS, because of the risk of severe peri-procedural complications including hemorrhage, hepatocellular injury, and thromboembolic events defined in the REMS.”
> “Healthcare settings that dispense and administer HEPZATO KIT must be enrolled, certified, and comply with the REMS requirements.”
> “Certified healthcare facilities must ensure that patients are assessed for severe peri-procedural complications during the procedure and for at least 72 hours following the procedure.”

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

<a id="topic-2.1.2.14-15"></a>

### Melphalan hepatic delivery system label: FOCUS single-arm efficacy in 91 treated participants

> “The efficacy of HEPZATO in hepatic-dominant metastatic uveal melanoma was based on the results from 91 patients who received HEPZATO via the HEPZATO KIT in the FOCUS Study (NCT02678572), a multicenter, open-label trial.”
> “The major efficacy outcome measures were objective response rate (ORR) and duration of response (DoR) using computed tomography (CT) or magnetic resonance imaging (MRI) assessed by an independent central review committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.”
> “Forty-three percent (43%) of patients underwent prior therapy for metastatic disease, including systemic therapy (25%), other surgeries or procedures (14%), and radiation (11%).”

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

| Outcome in the FOCUS trial | HEPZATO (N=91) |
| --- | --- |
| Objective response rate (95% CI) | “36.3% (26.4, 47.0)” |
| Complete response | “7.7%” |
| Partial response | “28.6%” |
| Number of responders | “n= 33” |
| Median duration of response, months (95% CI) | “14.0 (8.3, 17.7)” |

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

<a id="topic-2.1.2.14-16"></a>

### Melphalan hepatic delivery system label: serious and fatal adverse reactions and myelosuppression in FOCUS

> “Serious adverse reactions occurred in 45% of patients who received HEPZATO.”
> “Fatal adverse reactions occurred in 3 (3.2%) patients who were treated with HEPZATO; these included cardiac arrest, acute hepatic failure and bacterial peritonitis.”
> “HEPZATO was permanently discontinued due to adverse reactions in 18% of patients with neutropenia being the most common adverse reaction (3.2%) requiring permanent discontinuation.”
> “In the 95 patients who received HEPZATO in the FOCUS trial, 68% had Grade 3 or 4 myelosuppression.”

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

<a id="topic-2.1.2.14-17"></a>

### Nivolumab label: melanoma indication and dosing with ipilimumab

> “OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.”
> “Adult and pediatric patients weighing 40 kg or greater: 1 mg/kg followed by ipilimumab 3 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)”

Source: [Bristol-Myers Squibb OPDIVO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125554s138lbl.pdf)

<a id="topic-2.1.2.14-18"></a>

### Nivolumab label: ocular melanoma excluded from the first-line CHECKMATE-066 trial

> “CHECKMATE-066 (NCT01721772) was a multicenter, double-blind, randomized (1:1) trial in 418 patients with BRAF V600 wild-type unresectable or metastatic melanoma.”
> “Key eligibility criteria included histologically confirmed, unresectable or metastatic, cutaneous, mucosal, or acral melanoma; no prior therapy for metastatic disease; completion of prior adjuvant or neoadjuvant therapy at least 6 weeks prior to randomization; ECOG performance status 0 or 1; absence of autoimmune disease; and absence of active brain or leptomeningeal metastases. The trial excluded patients with ocular melanoma.”

Source: [Bristol-Myers Squibb OPDIVO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125554s138lbl.pdf)

<a id="topic-2.1.2.14-19"></a>

### Nivolumab label: serious adverse reactions with nivolumab plus ipilimumab in CHECKMATE-067 and the immune-mediated adverse reaction warning

> “The most frequent (≥10%) serious adverse reactions in the OPDIVO and ipilimumab arm and the OPDIVO arm, respectively, were diarrhea (13% and 2.2%), colitis (10% and 1.9%), and pyrexia (10% and 1%).”
> “Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting treatment with a PD-1/PD-L1 blocking antibody.”

Source: [Bristol-Myers Squibb OPDIVO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125554s138lbl.pdf)

<a id="topic-2.1.2.14-20"></a>

### Ipilimumab label: melanoma indication and combination dosing with nivolumab

> “YERVOY, as a single agent or in combination with nivolumab, is indicated for the treatment of unresectable or metastatic melanoma in adult and pediatric patients 12 years and older.”
> “YERVOY 3 mg/kg every 3 weeks for a maximum of 4 doses. (2.2)”
> “YERVOY 3 mg/kg immediately following nivolumab 1 mg/kg on the same day, every 3 weeks for 4 doses. After completing 4 doses of the combination, administer nivolumab as a single agent as recommended in the Full Prescribing Information for nivolumab. (2.2)”

Source: [Bristol-Myers Squibb YERVOY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125377s140lbl.pdf)

<a id="topic-2.1.2.14-21"></a>

### Ipilimumab label: ocular melanoma excluded from CHECKMATE-067 and immune-mediated adverse reactions

> “CHECKMATE-067 (NCT01844505) was a multicenter, randomized (1:1:1), double-blind trial in which 945 patients with previously untreated, unresectable or metastatic melanoma were randomized to one of the following arms: YERVOY and nivolumab, nivolumab, or YERVOY.”
> “Patients were required to have completed adjuvant or neoadjuvant treatment at least 6 weeks prior to randomization and have no prior treatment with anti-CTLA-4 antibody and no evidence of active brain metastasis, ocular melanoma, autoimmune disease, or medical conditions requiring systemic immunosuppression.”
> “Immune-mediated adverse reactions can occur at any time after starting YERVOY.”

Source: [Bristol-Myers Squibb YERVOY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125377s140lbl.pdf)

<a id="topic-2.1.2.14-22"></a>

### Pembrolizumab label: melanoma indication, dose, and uveal melanoma excluded from KEYNOTE-002

> “KEYTRUDA® is indicated for the treatment of patients with unresectable or metastatic melanoma.”
> “Melanoma: 200 mg every 3 weeks or 400 mg every 6 weeks; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics. (2.2)”
> “The efficacy of KEYTRUDA was investigated in KEYNOTE-002 (NCT01704287), a multicenter, randomized (1:1:1), active-controlled trial in 540 patients randomized to receive one of two doses of KEYTRUDA in a blinded fashion or investigator’s choice chemotherapy.”
> “The trial excluded patients with uveal melanoma and active brain metastasis.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s195lbl.pdf)

<a id="topic-2.1.2.14-23"></a>

### Nivolumab and relatlimab label: melanoma indication, dose, and uveal melanoma excluded from RELATIVITY-047

> “OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.”
> “The recommended dosage of OPDUALAG for adult patients and pediatric patients 12 years of age or older who weigh at least 40 kg is 480 mg nivolumab and 160 mg relatlimab administered intravenously every 4 weeks until disease progression or unacceptable toxicity occurs.”
> “The efficacy of OPDUALAG was investigated in RELATIVITY-047 (NCT03470922), a randomized (1:1), double-blinded trial in 714 patients with previously untreated metastatic or unresectable Stage III or IV melanoma.”
> “The trial excluded patients with active autoimmune disease, medical conditions requiring systemic treatment with moderate or high dose corticosteroids or immunosuppressive medications, uveal melanoma, and active or untreated brain or leptomeningeal metastases.”

Source: [Bristol-Myers Squibb OPDUALAG prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761234s011lbl.pdf)

<a id="topic-2.1.2.14-24"></a>

### Dacarbazine label: metastatic malignant melanoma indication, boxed warning, and intravenous dosing

> “Dacarbazine for Injection, USP is indicated in the treatment of metastatic malignant melanoma.”
> “Hemopoietic depression is the most common toxicity with dacarbazine (see WARNINGS ).”
> “Hepatic necrosis has been reported (see WARNINGS ).”
> “The recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals.”
> “An alternate recommended dosage is 250 mg/square meter body surface/day I.V. for 5 days. Treatment may be repeated every 3 weeks.”

Source: [Hikma Dacarbazine for Injection prescribing information (2020)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d81315c-7021-4091-b703-ad135390c936)

<a id="topic-2.1.2.14-25"></a>

### Dacarbazine label: nausea and vomiting, myelosuppression, and administration setting

> “Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses.”
> “Leukopenia and thrombocytopenia may be severe enough to cause death.”
> “Hospitalization is not always necessary but adequate laboratory study capability must be available. Extravasation of the drug subcutaneously during intravenous administration may result in tissue damage and severe pain.”

Source: [Hikma Dacarbazine for Injection prescribing information (2020)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d81315c-7021-4091-b703-ad135390c936)

<a id="topic-2.1.2.14-26"></a>

### RP2 plus nivolumab versus nivolumab plus ipilimumab: phase 2/3 trial in immune checkpoint inhibitor-naive metastatic uveal melanoma

> “The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.”
> “Patients with confirmed diagnosis of metastatic Uveal melanoma not amenable to surgical resection.”
> “Any exposure to immune checkpoint inhibitor (ICIs) since the time of first being diagnosed with uveal melanoma.”

Source: [ClinicalTrials.gov NCT06581406](https://clinicaltrials.gov/study/NCT06581406)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
